ATE429511T1 - Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene - Google Patents

Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene

Info

Publication number
ATE429511T1
ATE429511T1 AT02724190T AT02724190T ATE429511T1 AT E429511 T1 ATE429511 T1 AT E429511T1 AT 02724190 T AT02724190 T AT 02724190T AT 02724190 T AT02724190 T AT 02724190T AT E429511 T1 ATE429511 T1 AT E429511T1
Authority
AT
Austria
Prior art keywords
gene
diagnostic
therapeutic purposes
genes
knowledge base
Prior art date
Application number
AT02724190T
Other languages
English (en)
Inventor
Alexander Olek
Kurt Berlin
Original Assignee
Epigenomics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenomics Ag filed Critical Epigenomics Ag
Application granted granted Critical
Publication of ATE429511T1 publication Critical patent/ATE429511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
AT02724190T 2001-03-01 2002-03-01 Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene ATE429511T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27254901P 2001-03-01 2001-03-01
PCT/EP2002/002255 WO2002070742A1 (en) 2001-03-01 2002-03-01 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes

Publications (1)

Publication Number Publication Date
ATE429511T1 true ATE429511T1 (de) 2009-05-15

Family

ID=23040261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02724190T ATE429511T1 (de) 2001-03-01 2002-03-01 Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene

Country Status (7)

Country Link
US (1) US20020137086A1 (de)
EP (1) EP1364069B1 (de)
JP (1) JP2004529630A (de)
AT (1) ATE429511T1 (de)
CA (1) CA2439854A1 (de)
DE (1) DE60232059D1 (de)
WO (1) WO2002070742A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955794B2 (en) 2000-09-21 2011-06-07 Illumina, Inc. Multiplex nucleic acid reactions
US7611869B2 (en) 2000-02-07 2009-11-03 Illumina, Inc. Multiplexed methylation detection methods
US7582420B2 (en) 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
US8076063B2 (en) 2000-02-07 2011-12-13 Illumina, Inc. Multiplexed methylation detection methods
WO2003027321A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US20110151438A9 (en) * 2001-11-19 2011-06-23 Affymetrix, Inc. Methods of Analysis of Methylation
AU2003212878A1 (en) * 2002-01-30 2003-09-02 Epigenomics Ag Identification of cell differentiation states based on methylation patterns
WO2004020662A2 (en) * 2002-08-27 2004-03-11 Epigenomics Ag Method and nucleic acids for the analysis of breast cell proliferative disorders
US20060094016A1 (en) * 2002-12-02 2006-05-04 Niall Gormley Determination of methylation of nucleic acid sequences
WO2004071267A2 (en) * 2003-02-11 2004-08-26 Roche Diagnostics Gmbh Diagnosis of colorectal cancer by detection of nicotinamide n-methyltransferase in a stool sample
WO2004087957A2 (en) * 2003-04-03 2004-10-14 Oncomethylome Sciences S.A. Hypermethylated genes and cervical cancer
US20040236603A1 (en) * 2003-05-22 2004-11-25 Biospect, Inc. System of analyzing complex mixtures of biological and other fluids to identify biological state information
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
WO2004108960A2 (en) * 2003-06-09 2004-12-16 Decode Genetics Ehf. Methods for predicting drug efficacy in patients afflicted with hypertension
WO2005024064A2 (en) * 2003-09-11 2005-03-17 University College Cork - National University Of Ireland, Cork; A detection method for autism and related disorders
WO2005038046A1 (en) * 2003-10-14 2005-04-28 Bionomics Limited Methylation-based diagnostic method
US20050244973A1 (en) * 2004-04-29 2005-11-03 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
US20080249118A1 (en) * 2004-05-17 2008-10-09 Heiko Hermeking Silencing of Tumor-Suppressive Genes by Cpg-Methylation in Prostate Cancer
AU2005323173A1 (en) 2004-12-01 2006-07-13 The Curators Of The University Of Missouri Modulator of alpha-synuclein toxicity
CA2593546A1 (en) * 2004-12-02 2006-07-06 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
US20060134650A1 (en) * 2004-12-21 2006-06-22 Illumina, Inc. Methylation-sensitive restriction enzyme endonuclease method of whole genome methylation analysis
US7588894B2 (en) * 2005-02-01 2009-09-15 John Wayne Cancern Institute Use of ID4 for diagnosis and treatment of cancer
CA2608198A1 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US20070015183A1 (en) * 2005-06-03 2007-01-18 The General Hospital Corporation Biomarkers for huntington's disease
US20060292585A1 (en) * 2005-06-24 2006-12-28 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
WO2007003397A2 (en) * 2005-07-01 2007-01-11 Epigenomics Ag Method and nucleic acids for the improved treatment of cancers
WO2007039291A2 (en) * 2005-10-03 2007-04-12 Epigenomics Ag Methods, apparatus and nomograms to determine prostate cancer progression
US20080254470A1 (en) * 2005-10-03 2008-10-16 Epigenomics Ag Methods and Nucleic Acids For the Analysis of Gene Expression Associated With the Prognosis of Cell Proliferative Disorders
US20070207467A1 (en) * 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
GB0609498D0 (en) * 2006-05-12 2006-06-21 Oncomethylome Sciences S A Novel methylation marker
US20070281305A1 (en) * 2006-06-05 2007-12-06 Sean Wuxiong Cao Detection of lymph node metastasis from gastric carcinoma
CA2659082A1 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
WO2008096146A1 (en) 2007-02-07 2008-08-14 Solexa Limited Preparation of templates for methylation analysis
JP5415963B2 (ja) * 2007-02-21 2014-02-12 オスロ ユニベルシテートシケヒュース ホーエフ 新しい癌マーカー
US7844609B2 (en) * 2007-03-16 2010-11-30 Expanse Networks, Inc. Attribute combination discovery
US20100256001A1 (en) * 2007-04-03 2010-10-07 The Scripps Research Institute Blood biomarkers for mood disorders
US20090155788A1 (en) * 2007-05-22 2009-06-18 Abbas Alexander R Gene expression markers for inflammatory bowel disease
KR101035007B1 (ko) 2007-06-20 2011-05-17 가톨릭대학교 산학협력단 총량 감지 유전자군을 이용하여 위암 발생, 진행 여부 및 소인 추정에 필요한 데이터를 수집하는 방법, 그 프라이머 및 키트
US20090043752A1 (en) * 2007-08-08 2009-02-12 Expanse Networks, Inc. Predicting Side Effect Attributes
WO2009037635A2 (en) * 2007-09-17 2009-03-26 Koninklijke Philips Electronics N. V. Method for the analysis of breast cancer disorders
EP2217728A4 (de) 2007-11-30 2011-01-05 Genomictree Inc Diagonsekit und chip für blasenkrebs mit blasenkrebsspezifischem methylierungsmarkergen
US9670552B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US10113203B2 (en) 2007-11-30 2018-10-30 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9670551B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9797017B2 (en) * 2007-11-30 2017-10-24 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9783857B2 (en) * 2007-11-30 2017-10-10 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
WO2009071920A2 (en) * 2007-12-07 2009-06-11 Oncomethylome Sciences Sa Methods for identifying epigenetically silenced genes and novel tumour suppressor genes
WO2009079208A2 (en) * 2007-12-17 2009-06-25 Siemens Healthcare Diagnostics Inc. Methylation markers for cancer
WO2009086306A1 (en) * 2007-12-21 2009-07-09 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
CA2724343A1 (en) 2008-05-15 2009-11-19 Ribomed Biotechnologies, Inc. Methods and reagents for detecting cpg methylation with a methyl cpg binding protein (mbp)
US8200509B2 (en) 2008-09-10 2012-06-12 Expanse Networks, Inc. Masked data record access
US20100063830A1 (en) * 2008-09-10 2010-03-11 Expanse Networks, Inc. Masked Data Provider Selection
US20100076988A1 (en) * 2008-09-10 2010-03-25 Expanse Networks, Inc. Masked Data Service Profiling
US20100076950A1 (en) * 2008-09-10 2010-03-25 Expanse Networks, Inc. Masked Data Service Selection
US20100070292A1 (en) * 2008-09-10 2010-03-18 Expanse Networks, Inc. Masked Data Transaction Database
US20100063865A1 (en) * 2008-09-10 2010-03-11 Expanse Networks, Inc. Masked Data Provider Profiling
US7917438B2 (en) * 2008-09-10 2011-03-29 Expanse Networks, Inc. System for secure mobile healthcare selection
US20100063835A1 (en) * 2008-09-10 2010-03-11 Expanse Networks, Inc. Method for Secure Mobile Healthcare Selection
US8541207B2 (en) * 2008-10-22 2013-09-24 Illumina, Inc. Preservation of information related to genomic DNA methylation
WO2010074924A1 (en) * 2008-12-23 2010-07-01 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
US8108406B2 (en) 2008-12-30 2012-01-31 Expanse Networks, Inc. Pangenetic web user behavior prediction system
US8386519B2 (en) 2008-12-30 2013-02-26 Expanse Networks, Inc. Pangenetic web item recommendation system
US8463554B2 (en) 2008-12-31 2013-06-11 23Andme, Inc. Finding relatives in a database
EP2955235A3 (de) * 2009-01-30 2016-03-02 Koninklijke Philips N.V. Verfahren zur subklassifizierung von mammakarzinomen
RU2011141720A (ru) 2009-03-15 2013-04-27 Рибомед Байотекнолоджиз, Инк. Молекулярное обнаружение, основанное на абскрипции
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
EP2558594A2 (de) * 2010-04-16 2013-02-20 Koninklijke Philips Electronics N.V. Verfahren zur analyse von brustkrebserkrankungen
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
JP6222202B2 (ja) * 2010-07-05 2017-11-01 ソニー株式会社 生体情報処理方法および装置、並びに記録媒体
JP5838557B2 (ja) 2010-07-05 2016-01-06 ソニー株式会社 生体情報処理方法および装置、並びに記録媒体
AU2013275761B2 (en) * 2012-06-14 2017-09-28 Aarhus Universitet Biomarkers for prostate cancer
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
KR101557183B1 (ko) * 2012-08-14 2015-10-02 충북대학교 산학협력단 방광암 예후 진단 마커
ES2859645T3 (es) 2013-03-14 2021-10-04 Mayo Found Medical Education & Res Detección de neoplasia
US20140287948A1 (en) * 2013-03-15 2014-09-25 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
AU2014227891A1 (en) 2013-03-15 2015-10-08 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
EP4344705A3 (de) * 2013-03-15 2024-10-02 Sera Prognostics, Inc. Biomarker und verfahren zur vorhersage von präeklampsie
KR101553870B1 (ko) 2013-10-11 2015-09-17 서울대학교산학협력단 Dna 탈메틸효소를 이용한 pcr 기반의 dna 메틸화 분석 방법
WO2015109107A1 (en) * 2014-01-15 2015-07-23 Cal Poly Pomona Foundation, Inc. Treatment and diagnosis of huntington's disease
EP2915883A1 (de) * 2014-03-07 2015-09-09 Ruprecht-Karls-Universität Heidelberg Nichtinvasives Assay-Verfahren zur Früherkennung von Krebs
JP6413163B2 (ja) * 2014-07-17 2018-10-31 国立大学法人 東京大学 クリティカルコロナイゼーション創傷又は感染創傷の判定用キット、判定方法及び試験方法
EP3230314B1 (de) 2014-12-08 2023-05-03 Berg LLC Verwendung von markern einschliesslich filamin a bei der diagnose und behandlung von prostatakrebs
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
ES2955883T3 (es) 2015-06-19 2023-12-07 Sera Prognostics Inc Pares de biomarcadores para la predicción del parto prematuro
KR20250172724A (ko) 2015-08-31 2025-12-09 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 위 신생물 검출 방법
US11078543B2 (en) * 2016-04-14 2021-08-03 Mayo Foundation For Medical Education And Research Detecting pancreatic high-grade dysplasia
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3624821A4 (de) 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University Enzastaurin und fragile histidintriad (fhit)-erhöhende mittel zur behandlung von pulmonaler hypertonie
AU2018317902B2 (en) 2017-08-18 2025-02-20 Sera Prognostics, Inc. Pregnancy clock proteins for predicting due date and time to birth
JP7320345B2 (ja) * 2017-10-27 2023-08-03 シスメックス株式会社 遺伝子解析方法、遺伝子解析装置、遺伝子解析システム、プログラム、および記録媒体
KR102129066B1 (ko) * 2018-04-11 2020-07-15 한국과학기술연구원 항암 보조치료법의 선택을 위한 혈액 마커 및 이를 이용한 치료법 선택의 방법
CN108866189B (zh) * 2018-07-12 2022-03-01 吉林大学 一种喉鳞状细胞癌易感性预测试剂盒及系统
CN108841959B (zh) * 2018-07-12 2022-03-01 吉林大学 一种口腔及头颈部恶性肿瘤易感性预测试剂盒及系统
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及系统
KR102806666B1 (ko) * 2018-10-30 2025-05-12 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 샘플 품질 평가 방법
KR102039529B1 (ko) * 2019-01-31 2019-11-01 주식회사 에스씨엘헬스케어 대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도
RU2698453C1 (ru) * 2019-04-02 2019-08-27 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ прогнозирования клинического течения гемофилии с уровнем активности факторов VIII, IX
CN110317871B (zh) * 2019-07-11 2022-06-07 广州康立明生物科技股份有限公司 一种基因标志物组合及其应用
KR20240137114A (ko) 2019-08-05 2024-09-19 시어 인코퍼레이티드 샘플 제조, 데이터 생성, 및 단백질 코로나 분석을 위한 시스템 및 방법
CN110951873A (zh) * 2019-12-03 2020-04-03 中山大学 一种骨肉瘤标志物及其应用、试剂盒
EP4217508B1 (de) * 2020-09-22 2026-01-28 The Secretary Of State For Defence Vorrichtung, kits und verfahren zur vorhersage der entwicklung von sepsis
US20240002943A1 (en) * 2020-12-04 2024-01-04 Evonik Operations Gmbh A method for classifying the gut inflammation status in avian species
CN116536279B (zh) * 2022-01-25 2023-11-14 杭州馨海酶源生物科技有限公司 一种基因工程菌及在制备去氢表雄酮上的应用
CN115631857B (zh) * 2022-04-01 2023-06-23 洛兮医疗科技(杭州)有限公司 甲状腺癌cd8+t细胞免疫相关基因预后预测模型
CN116004795B (zh) * 2022-11-02 2025-11-28 南京鼓楼医院 一种基于cyp51a1基因表达检测辅助诊断系统性红斑狼疮的试剂盒
CN117418013A (zh) * 2023-12-19 2024-01-19 四川省肿瘤医院 用于检测卵巢癌细胞MyD88基因5'URR CpG岛甲基化水平的引物、方法及其应用
CN117947169B (zh) * 2024-02-02 2024-08-20 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 早期检测子宫内膜癌的甲基化基因标志物组合、多重pcr检测试剂盒及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525300A (en) * 1993-10-20 1996-06-11 Stratagene Thermal cycler including a temperature gradient block
AU2222000A (en) * 1998-12-31 2000-07-31 St. Jude Children's Research Hospital A tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein
DE19905082C1 (de) * 1999-01-29 2000-05-18 Epigenomics Gmbh Verfahren zur Identifikation von Cytosin-Methylierungsmustern in genomischen DNA-Proben
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
AU7412900A (en) * 1999-08-22 2001-04-10 Dot Diagnostics B.V. Improved method for nucleotide detection and devices used therein

Also Published As

Publication number Publication date
EP1364069A1 (de) 2003-11-26
JP2004529630A (ja) 2004-09-30
WO2002070742A1 (en) 2002-09-12
DE60232059D1 (de) 2009-06-04
EP1364069B1 (de) 2009-04-22
US20020137086A1 (en) 2002-09-26
CA2439854A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
DE60232059D1 (de) Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
Harris et al. Noise-cancelling repeat finder: uncovering tandem repeats in error-prone long-read sequencing data
Takahata A genetic perspective on the origin and history of humans
DK0950113T3 (da) Detektion af genetisk prædisposition for synstruende diabetisk retinopati
ATE357537T1 (de) Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren
ATE404695T1 (de) Einfache katalytische dna-biosensoren für ionen auf grundlage von farbveränderungen
ATE225406T1 (de) Ein screeningsystem auf zellbasis
DE69931608D1 (de) Verfahren zur bestimmung von dna-längenpolymorphismen
EP3483286A1 (de) Sequenzanalyseverfahren, sequenzanalysevorrichtung, referenzsequenzerzeugungsverfahren und referenzsequenzerzeugungsvorrichtung
Goossens et al. Detection of minor variants in Mycobacterium tuberculosis whole genome sequencing data
Lovett The applications of single-cell genomics
Hofreiter Drafting human ancestry: What does the Neanderthal genome tell us about hominid evolution? Commentary on Green et al.(2010)
Kumar et al. Simple and efficient way to detect small polymorphic bands in plants
SE8700821L (sv) Sett och reagenskit for kvantifiering av nukleinsyramolekyler
Lee et al. Genetic resolution of applied biosystems™ precision ID Ancestry panel for seven Asian populations
Le et al. Cytokine-induced memory-like responses in endothelial cells link chronic inflammation to vascular disease risk
Kitsou et al. Limitations of current high-throughput sequencing technologies lead to biased expression estimates of endogenous retroviral elements
ATE508201T1 (de) Verfahren zur generierung eines gentechnisch veränderten organismus für das wirksubstanzscreening
DE60327048D1 (de) Verfahren zur in vivo quantifizierung von nukleinsäuren
Klostermeier et al. A tissue-specific landscape of sense/antisense transcription in the mouse intestine
DE69710469D1 (de) Diagnoseverfahren und vorrichtung zum nachweis der prädisposition zu bestimmten krankheitszuständen, insbesondere osteoporose, auf basis von il-6 genpolymorphismus
Aoki et al. PCR-based screening tests for SARS-CoV-2 mutations: what is the best way to identify variants?
Spencer et al. A screen for short-range paracrine interactions
Takeshita et al. Geographical north-south decline in DNASE1* 2 in Japanese populations
DE602005026412D1 (de) Zweidimensionale strangform- und längenabhängige trennung von nukleinsäurefragmenten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties